



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/761,717

01/20/2004

Yukun Sun

57783.8004.US00

3780

34055

7590

05/16/2008

PERKINS COIE LLP
POST OFFICE BOX 1208
SEATTLE, WA 98111-1208

EXAMINER

LIU, SAMUEL W

ART UNIT

PAPER NUMBER

1656

MAIL DATE

DELIVERY MODE

05/16/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10761717	1/20/2004	SUN ET AL.	57783.8004.US00

PERKINS COIE LLP
POST OFFICE BOX 1208
SEATTLE, WA 98111-1208

EXAMINER

SAMUEL W. LIU

ART UNIT	PAPER
----------	-------

1656

20080513

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Neither the applicants' amendment filed 2/5/07 nor amendment filed 1/31/07 reflects the invention of the elected claims 1-16 which was examined in the Office action mailed 7/31/06. This is because claims 1-16 are directed to a method of producing GLP-1(7-36) polypeptide by ligating cohesive ends to form a hybrid site and cloning a polynucleotide into "a vector N copies" wherein said polynucleotide contains said hybrid site on the end of each gene encoding GLP-1 polypeptide, whereas claims filed 2/5/07 and 1/31/07 are drawn to a method of producing GLP-1(7-36) polypeptide by sequentially cloning the polynucleotide which contains first and second restriction endonuclease sites at one end, and third or/and fourth restriction endonuclease sites at the other end thereof, and contains a nucleotide sequence encoding a GLP-1 polypeptide. The method produces the vector comprising multiple copies of the gene encoding each GLP-1(7-36) polypeptide, and produces fusion protein comprising the multiple copies of said polypeptides. Thus, it appears that the amended claims 1-24 filed 1/31/07 and claims 37-58 filed 2/5/07 are patentably distinct from said claims 1-16 filed 1/17/06; and therefore, neither the amendment filed 2/5/07 nor the amendment filed 1/31/07 is considered to be responsive.

Since the submission of the amendments discussed above appears to be a bona fide attempt to provide a complete reply to the prior Office action mailed 7/31/06, applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office action. This time period may be extended pursuant to 37 CFR 1.136(a). If a notice of appeal and the fee set forth in 37 CFR 1.17(e) were filed prior to or with the payment of the fee set forth in 37 CFR 1.17(r), the payment of the fee set forth in 37 CFR 1.17(r) by applicant is construed as a request to dismiss the appeal and to continue prosecution under 37 CFR 1.129(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Wei Liu whose telephone number is 571-272-0949. The examiner can normally be reached from 9:00 a.m. to 5:00 p.m. on weekdays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon, can be reached on (571) 272-0931. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

/Karen Cochrane Carlson, Ph.D./
Primary Examiner, Art Unit 1656